On 14 December 2018, orphan designation (EU/3/18/2121) was granted by the European Commission to Ability Pharmaceuticals SL, Spain, for sodium 2-hydroxylinoleate (also known as ABTL0812) for the treatment of biliary tract cancer.

Key facts

Active substance
Sodium 2-hydroxylinoleate
Disease / condition
Treatment of biliary tract cancer
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Ability Pharmaceuticals SL
Edifici Eureka
Campus de la UAB
08193 Bellaterra
Tel. +34 935 824 411

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating